Clinical Trials And EfficacyThe positive view on lead asset ixo-vec, believed to be a best-in-class gene therapy candidate for wet age-related macular degeneration, remains unchanged.
Financial StabilityThe $125.7M in cash and equivalents is anticipated to fund operations into the second half of 2025, supporting the ongoing pivotal program.
Patient Enrollment And Study ProgressPatient enrollment for ARTEMIS, the first P3 study for ixo-vec, is ahead of schedule.